Document is current
Any future updates will be listed below
-
Authors
Sureda, Anna https://orcid.org/0000-0002-1238-6970
Pavlovsky, Astrid
Haidar, Dalah
Kristo, Fjoralba
Stache, Vanessa
Zomas, Athanasios
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals International AG – Singapore Branch
- License Information
-
More Information
Article History
Received: 20 December 2024
Revised: 16 February 2025
Accepted: 14 March 2025
First Online: 8 April 2025
Competing interests
: Anna Sureda reports honoraria from Takeda Pharmaceuticals, Bristol Myers Squibb/Celgene, Merck Sharp & Dohme, Janssen, Amgen, Novartis, Kite/Gilead, Sanofi, Roche, and Alexion; consultancy for Takeda Pharmaceuticals, Bristol Myers Squibb/Celgene, Novartis, Janssen, Gilead, and Sanofi; speakers bureau for Takeda Pharmaceuticals; research support from Takeda Pharmaceuticals and Bristol Myers Squibb/Celgene; and Presidency of the European Society for Blood and Marrow Transplantation. Astrid Pavlovsky reports grants or contracts from Takeda Pharmaceuticals; consulting fees from Takeda Pharmaceuticals, Bristol Myers Squibb, and Merck Sharp & Dohme; and support from Roche and Takeda Pharmaceuticals to attend meetings. Dalah Haidar, Fjoralba Kristo, Vanessa Stache, and Athanasios Zomas are employees of Takeda Pharmaceuticals and hold shares in the company.
